In this study, we aimed to prepare bilayer tablets of Glimepiride in floating drug delivery and Metformin in sustained release formulation. Glimepiride is chosen in floating drug delivery to overcome the gastric irritation and gastric emptying time. Glimepiride was prepared by different polymers such as guar gum, xanthan gum, carbopol and sodium bicarbonate act as effervescent agent, and other excipients were mixed and compressed by direct compression as the first layer. Metformin was chosen in sustained release to reduce dose frequency using different polymer HPMC K100M, methylcellulose, PVP K30 in different ratio and other excipients were mixed and compressed as the second layer. The first layer and second layer are combined as a bilayer tablet. Tablets were evaluated for hardness, friability, thickness, weight variation; the In vitro studies were done for all formulation. Among all formulation, F2 was selected as best formulation and release kinetics studies were evaluated for formulation F2.
INTRODUCTION
Diabetes mellitus is the most common endocrine disorder. It is a chronic condition, causes by hyperglycemia due to impaired insulin secretion. DM has two types, type-1 (Insulin dependent diabetes mellitus) this type of patients is due to lack of insulin production. In earlier this condition was called juvenile onset diabetes and type-2 (Non-insulin dependent diabetes mellitus) or maturity onset diabetes. Approximately 90-95%of diabetes population is affected by type-2 DM; it usually occurs in the age above 40 due to obesity (Sharma, H.P. et al., 2015) . Glimepiride act on sulphonylureas receptor. The receptor links to the ATP dependent K channel in the cell membrane of the islet beta cells. The receptor activates to close the K channel and cell membrane to depolarize. These occur calcium influx into the cell. They are effective only in the presence of a functioning pancreas (Satoskar, R.S. et al., 2012) . Glimepiride is used in floating drug delivery to retain the drug for a long period of time in the stomach (Dheeraj, D.R. et al., 2015) . Metformin does not stimulate insulin secretion from the pancreas. But the presence of external or internal insulin is necessary for its action. Several mechanisms are involved in the anti-diabetic effect of metformin. It acts as an insulin sensitizer in the muscle and adipose tissue and reduces hyperinsulinemia. This action has a minor role in delaying glucose absorption and reduce the appetite which may be helpful in the obese subject. Metformin does not lower the blood sugar in a normal subject (Satoskar, R.S. et al., 2012) . Metformin is used in sustained drug dosage form to achieve a prolonged therapeutic effect by continuously releasing medication for a long period of time after administration. Metformin sustained release formulation are prepared to modify and improve the drug performance by increasing the duration of action and to decrease the frequency of dose, to decrease the required dose, and to provide the uniform drug release (Sahilhusen, I.J. et al., 2014) .
MATERIALS & METHODS

Materials used
Glimepiride gifted sample, Metformin gifted sample, Guar gum (SD Fine Chem limited), Xanthan gum (Himedia lab), Carbopol (Loba Chemie), Sodium bicarbonate (Kemphasol), Talc (Loba Chemie), Magnesium stearate (Himedia lab), Amaranth (Loba Chemie), HPMC K100M (Yarrow Chem), Methylcellulose (Loba Chemie), PVP K30 (Loba Chemie), Microcrystalline cellulose (Loba Chemie).
Formulation of Glimepiride floating layer
The tablet contains 2 mg of Glimepiride is prepared by direct compression method by using polymer in a different ratio. All ingredients were passed through sieve mesh no: 40 separately. Drug and polymer were mixed homogenously, and magnesium stearate and talc were added as lubricant and filler. All ingredients were mixed and weighted accurately and compressed in tablet punching machine (REMIK mini press 1) in low compression force (Vishal, G.K. et al., 2009 and Rajani, S. et al., 2013) (Table 1) .
Formulation of Metformin sustained release layer
The tablet contains 250 mg of Metformin was prepared by direct compression method by using polymer in a different ratio. All ingredient was passed through sieve mesh no: 40 separately. Drug and polymer were mixed homogenously, and magnesium stearate and microcrystalline cellulose were added as lubricant and filler. All ingredients were mixed and weighted accurately and compressed in a tablet punching machine (REMIK mini press 1) (Sayed, I.A. et al., 2009) (Table 2) .
Formulation of bilayer tablet
Both layers were compressed and prepared as a bilayer tablet of glimepiride and metformin using a punching machine.
Evaluation of bilayer tablet
Weight variation test: To study weight variation, 6 tablets of formulation were studied; the test was performed according to the standard IP. The weight was calculated in the given formula (Quazi, R. et al., 2015) .
Tablet thickness: The thickness of the tablet was important for uniformity of tablet size. Six tablets were selected randomly, and vernier-calliper scale was used to measure the thickness of the tablet, which permits accurate measurement (Quazi, R. et al., 2015) .
Hardness of tablet
Indication of strength against resistance of tablet to capping, abrasion or breakage under storage, temperature, handling before usage. Hardness is the measure of the force required to break the tablet a specific device. The hardness of six tablets is determined by Monsanto hardness tester. Hardness is measured in kg /cm 2 (Quazi, R. et al., 2015) .
Friability test
Tablet friability was determined with Inveka friabilator. Accurately weight the tablet, and place the tablet in the drum. Rotate the drum for 4 minutes 100 rotations and removed the tablet. The drum was attached to the horizontal axis of a device that rotates at 25 ± 1 rpm. Thus at each turn the tablet roll or slide and fall onto the drum wall or onto each other. A maximum mean loss from three samples of not more than 1% was considered acceptable for most products (Quazi, R. et al., 2015) .
Disintegration time
Disintegration test was done in tablet disintegration apparatus in six rack basket. The tablet is placed in a basket in a buffer medium (pH 1.2). Time is noted when the tablet is completely dissolved in the basket. This time was taken as disintegration time (Quazi, R. et al., 2015) .
Floating lag time and floating capacity
Time takes to reach the surface of the water was floating lag time and period of time than constantly floats on the surface of the medium was floating capacity. This procedure was done in a dissolution vessel contains 0.1 N HCL as a buffer medium (pH 1.2). Time was noted between, the tablet introduced into the buffer medium and time takes to reach the upper surface of the tablet. This time was taken as floating lag time. The time that remains on the surface on the medium was taken as floating capacity (Quazi, R. et al., 2015) .
In vitro evaluation
Drugs release studies were carried out in a dissolution test apparatus using a specified volume of 900 ml of dissolution media maintained at 37°C ± 0.5°C. The tablet was directly placed in the medium and immediately operates the apparatus at specified rate within the time interval specified (1hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, 8hr & 15hr) withdraw a specimen from zone midway between the surface of the dissolution medium and the top of the rotating paddle not less than 10mm from the vessel wall and same volume of fresh medium is replaced each time. The samples are filtered and from the filtrate 1 ml was taken and diluted to 10 ml. These samples were analysed, and further calculation was carried out to get drug release. The In vitro dissolution kinetic parameter, dissolution rate constant, correlation coefficient and dissolution efficiency were calculated (Xiaole, Q. et al., 2015) .
Kinetics study of drug release
The kinetics study of drug release was important to demonstrate the behavior of drug release by a mathematical model. The drug release is compared with the pharmacokinetics model to identify the release obeys zero order or first order kinetics study. The mathematical model has four types, zero or first order, Higuchi (Jun, J. et al., 2016) Korsemeyer Peppas plot (Pamu, S. et al., 2014) . This used to calculate the correlation coefficient (r) value (Mariyam, A. et al., 2012) RESULTS AND DISCUSSION Formulation of bilayer tablet 
Physiochemical evaluation
Weight variation test: The results of the weight variation were shown in table 4. All formulations passed weight variation test as per the pharmacopoeia limits ± 5 %.
Tablet thickness: The thickness of all formulations was uniform with a minimum deviation as shown in table 4. The range varies from 0.555 to 0.567 cm.
Hardness test: The hardness of formulation was shown in table 4 and found that it was 2.5 ± 0.00 Kg/cm 2 to 5 ± 0.00 Kg/cm 2 for formulation F2 and F8 all other formulations were within the limits as shown in the table Friability test: Friability of below 1% was indicated as good in the strength of tablet (Table 3) .
Floating lag time and capacity: Floating lag time for each formulation were shown in table no 5, and the range varies from 60 secs to 240 sec, and floating capacity for all formulation was shown in table 5 and tablet remains more than 15 hours (Table 4) .
In vitro drug release of a bilayer tablet of Glimepiride and Metformin In vitro release study was done for bilayer tablet, after placing in dissolution medium first layer and second layer separated from bilayer tablet and first layer floats on stomach pH 1.2 (0.1 N HCL) for 8 hours. The second layer of tablet remains in pH 1.2 for 2 hours and transferred to pH 7.4 phosphate buffer. Samples were collected in time interval (1hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, 8hr and 15hr). The two samples were analysed in UV spectrophotometer. Cumulative % drug release for all formulations is shown in the table 6 for Glimepiride floating tablet and table 7 for Metformin sustained release. The graph was plotted and shown in figure 2 Table 1: Formulation table for Glimepiride floating tablet  Ingredients  F1  F2  F3  F4  F5  F6  F7  F8  Glimepiride  2  2  2  2  2  2  2  2  Guar gum  15  15  25  25  15  15  25  25  Xanthan gum  15  25  15  25  15  25  15  25  Carbopol 934  15  15  15  15  25  25  25  25  Sodium bicarbonate  23  23  23  23  23  23  23  23  Talc  25  15  15  5  15  5  5  0  Magnesium stearate  5  5  5  5  5  5  5  5  Amaranth  qs  qs  qs  qs  qs  qs  qs  qs  Total  100  100  100  100  100  100 100 100 for Glimepiride and figure 3 for Metformin (Table  5) , (Figure 2 ), (Figure 3 ).
Kinetics study of drug release
First order kinetics study for glimepiride, the first order kinetics drug release means cumulative drug release was proportional to time, that means the rate of drug release is constant with time. The F2 is the best formulation and obeys first-order kinetics model, thus shown in figure 4 . Zero-order kinetics study for metformin, the zero-order kinetics drug release, the cumulative drug release was proportional to the time that means the rate of drug release was constant with time. The best formulation F2 obeys zero order kinetics model, thus shown in figure 5 . The diffusion process of drug release was revealed with the Higuchi model. The Higuchi describes the cumulative drug release is proportional to the square root of time. Higuchi was done for best formulation F2, the graph shown in figure 6 for Glimepiride, figure 7 for Metformin. Korsmeyer Peppas describes the log cumulative drug release was proportional to log time. Korsmeyer Peppas plot was used for best formulation F2; the graph is shown in figure 8 for Glimepiride, figure 9 for Metformin.
CONCLUSION
The present study concludes formulation of a bilayer tablet of Glimepiride floating layer and Metformin sustained release layer is possible, which passes all the physicochemical parameters within the limit such as tablet thickness, weight variation, friability, hardness, floating lag time and floating capacity. Among all formulations, F2 was selected based on in-vitro dissolution study with drug release up to 15 hours for metformin sustained release layer and 8 hours for glimepiride floating layer in the bilayer tablets. Release kinetics was done for best formulation F2 and followed first order for glimepiride and zero order for metformin. Which was studied for release mechanism; Higuchi shows higher linear with regression value of 0.993 for glimepiride and 0.981 for metformin respectively, and further Peppas n-value 0.982 for glimepiride and 0.989 for metformin, so it is considered as a non-fickian type of drug release.
